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ABSTRACT
Introduction: Gram-negative multi-drug
resistance is an emerging threat among
pediatric patients with cystic fibrosis (CF).
Ceftolozane/tazobactam (C/T) is an
extended-spectrum
cephalosporin/beta-lactamase inhibitor
combination that has been shown to maintain
activity against MDR P. aeruginosa isolates. The
understanding of C/T effectiveness in pediatric
patients is extremely limited. Minimum
inhibitory concentration (MIC) testing and
time-kill analyses were performed to better
understand the antimicrobial susceptibility
and potential role of C/T.
Methods: Non-duplicate clinical respiratory
MDR P. aeruginosa isolates (n = 5) from four
pediatric CF patients were identified. MICs were
determined for these isolates using CLSI broth
microdilution methods. Time-kill analyses were
performed using multiples of C/T alone, and
combinations of C/T 29 and 89 the MIC with
30 mg/L tobramycin or 80 mg/L amikacin for all
isolates. Cell counts were determined by serial
dilution plating.
Results: Isolates had variable susceptibilities to
C/T (range 0.5–8 mg/L), tobramycin (range 2
to[64 mg/L) and amikacin (range 8 to
[256 mg/L). Time-kill analyses revealed an
average of 0.71 (range -0.6 to 4.4), 1.50 (range
0.8–2.0) and 2.1 (range 1.2–3.4) log-kill at 49,
89 and 169 the C/T MIC, respectively. At a
tobramycin MIC of 32 mg/L, combination
therapy showed synergistic benefit when the
isolate was C/T susceptible. C/T and amikacin
combination therapy showed synergistic
activity at an amikacin MIC[256 mg/L when
C/T MIC was 2 mg/L (4.7 log-kill at 29 C/T MIC
and 4.0 log-kill at 89 C/T MIC).
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Conclusion: C/T appears to be a promising
treatment option for treatment of MDR P.
aeruginosa in pediatric CF patients, both alone
and in combination with tobramycin or
amikacin. Interestingly, the benefit of C/T
combination therapy with amikacin may be
more pronounced than with the addition of
tobramycin. Further evaluation of such
combination regimens in pediatric CF patients
is warranted.
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INTRODUCTION
The emergence of Gram-negative multi-drug
resistance is an ongoing threat. Pediatric
patients are not spared from these resistant
organisms. Of particular concern is emerging
Gram-negative resistance among pediatric
patients with cystic fibrosis (CF), who are
frequently exposed to broad-spectrum
antibiotic therapy for the treatment of acute
pulmonary exacerbations. Multi-drug-resistant
Pseudomonas aeruginosa often leaves CF patients
with few remaining treatment options and has a
significant detrimental impact on patient care,
including increased mortality [1]. New
antimicrobial agents have been developed for
the treatment of multi-drug-resistant organisms
(MDRO), but data in pediatric patients are
extremely limited.
Ceftolozane/tazobactam (ZerbaxaTM) was
approved by the FDA in December 2014 for the
treatment of complicated intra-abdominal and
urinary tract infections in adults [2].
Ceftolozane/tazobactam is an extended-spectrum
cephalosporin/beta-lactamase inhibitor
combination that has been shown to maintain
activity against MDR P. aeruginosa strains,
including respiratory strains from CF patients
[3–6]. Further evaluation of
ceftolozane/tazobactam drug activity against
MDR Pseudomonas isolates from pediatric patients
is warranted, given the potential utility of this
antibiotic in the treatment of MDR Pseudomonas
infection with limited remaining treatment
options. To better understand the antimicrobial
susceptibility and potential role of
ceftolozane/tazobactam in children—used alone,
and in combination with tobramycin or
amikacin—we performed Minimum inhibitory
concentrations (MICs) testing and time-kill




Five unique, non-duplicate clinical respiratory
isolates of MDR P. aeruginosa (resistant to C3
classes as defined by MIC testing in the hospital
microbiology laboratory) from four pediatric CF
patients age 6–17 years were included. These
isolates were collected at the discretion of the
physician providing clinical care at Connecticut
Children’s Medical Center from 2014 to 2016.
Isolates were identified through retrospective
review of the monthly institution MDRO
surveillance report and were obtained from the
hospital microbiology laboratory. Once
attained by the Center for Anti-Infective
Research and Development (Hartford Hospital,
Hartford, CT, USA), isolates were transferred
onto Trypticase Soy Agar with 5% sheep blood
(Becton, Dickinson, Sparks, MD, USA). The
minimum inhibitory concentrations (MICs)
were determined in triplicate using broth
microdilution methodology, and are listed in
Table 1. As recommended by Clinical
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Laboratory Standards Institute (CLSI), P.
aeruginosa 27853 was utilized as a quality
control strain and colony counts were
performed on each isolate to verify the correct
inoculum. All isolates were phenotypically
assessed against ceftolozane/tazobactam,
tobramycin, amikacin and other antibiotics
according to CLSI guidelines [7, 8]. The modal
MIC was used to characterize the isolate MICs.
Merck (Kenilworth, NJ, USA) provided
ceftolozane powder; tazobactam and all other
antibiotics were purchased from Sigma
Chemical (St. Louis, MO, USA).
Time-Kill Analyses
Time-kill analyses were performed on each of the
5 P. aeruginosa isolates. Each isolate was
subcultured twice on Trypticase Soy Agar with
5% sheep blood, (Becton, Dickinson) and a
bacterial suspension of 108 CFU/mL was
prepared. Mueller–Hinton Broth (MHB) was
inoculated with the bacterial suspension to a
final suspension approximately 5 9 105 CFU/mL.
Ceftolozane/tazobactam was added to achieve
concentrations of 0.59, 19, 29, 49, 89, 169 and
329 ceftolozane/tazobactam MICs alone, and
combinations of ceftolozane/tazobactam 29 and
89 the MIC with 30 mg/L tobramycin and
ceftolozane/tazobactam 29 and 89 the MIC
with 80 mg/L amikacin for all isolates.
Aminoglycoside concentrations were
determined to mimic peak concentrations
achieved with once-daily dosing in children. [9]
Control experiments without active compound
were conducted simultaneouslywith the time-kill
studies. Final volumes for each bacterium-drug
concentration were 10 mL and incubated at
37 C. Samples were taken from each sample at
0, 3, 6, and 24 h from the time of adding the drug.
Multiple 1:10 dilutions were made in saline and
sub-culturedontobloodagarplatesand incubated
for 18–24 h, and mean bacterial densities were
determined for each isolate. The minimal,
accurately countable number of CFU/mL was
determined to be 5 9 10-1 CFU/mL. [10] All
studies were conducted in duplicate on
different days, and the combined data are
presented as mean bacterial density (CFU/mL)
for all isolates. Bactericidal activity was defined
as a decrease of C3-log10 from baseline bacterial
density. Synergy was defined as a C2-log10
decrease in CFU/mL between the antibiotic
combination and its most active constituent
after 24 h when the number of surviving
organisms in the presence of the combination
was C2-log10 CFU/mL below the starting
inoculum [10].
Table 1 Minimum inhibitory concentrations of ﬁve P. aeruginosa
isolates against cefepime (FEP), ceftazidime (CAZ), ciproﬂoxacin
(CIP), colistin (CST), aztreonam (ATM), piperacillin/tazobactam
(TZP), meropenem (MEM), amikacin (AMK), fosfomycin (FOF),
tobramycin (TOB) and ceftolozane/tazobactam (C/T)
Isolate FEP CAZ CIP CST ATM TZP MEM AMK FOF TOB C/T
1554 64 [64 16 1 [64 256 16 32 64 [64 4
1555 (mucoid) [64 [64 4 1 64 128 4 16 64 [64 4
1556 8 2 1 0.5 4 4 0.25 16 64 2 0.5
1557 8 4 2 1 1 2 0.25 256 [64 32 2
1558 16 32 4 2 32 [256 [64 8 64 32 8
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Compliance with Ethics Guidelines
This study was approved by the Connecticut
Children’s Medical Center Institutional Review
Board, and does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Isolates had variable susceptibilities to
ceftolozane/tazobactam (range 0.5–8 mg/L),
tobramycin (range 2 to[64 mg/L) and
amikacin (range 8 to[256 mg/L). One isolate
(1555) was identified as a mucoid strain. Mean
bacterial densities over 24 h for all P. aeruginosa
isolates tested against multiples of their
ceftolozane/tazobactam MICs alone and in
combination with either tobramycin or
amikacin are shown in Fig. 1. Time-kill
analyses revealed an average of 0.71 (range
-0.6 to 4.4), 1.50 (range 0.8–2.0) and 2.1
(range 1.2–3.4) log-kill at 49, 89 and 169 the
ceftolozane/tazobactam MIC, respectively.
Bactericidal killing was generally not seen
until 169 ceftolozane/tazobactam MICs. At a
tobramycin MIC of 2 mg/L, combination
therapy with tobramycin and
ceftolozane/tazobactam 29 and 89 the MIC
showed a 4.3 and 3.7 log-kill, respectively. At a
tobramycin MIC of 32 mg/L, combination
therapy showed synergistic benefit when the
isolate was ceftolozane/tazobactam susceptible
(3.8 and 4.0 log-kill with 29 and 89 a
ceftolozane/tazobactam MIC of 2 mg/L,
respectively). No benefit of tobramycin
combination therapy was seen among
tobramycin non-susceptible isolates at a
tobramycin MIC[64 mg/L.
When compared to the extent of killing with
amikacin therapy alone, there was no
additional benefit of amikacin and
ceftolozane/tazobactam combination therapy
at an amikacin MIC of 16 mg/L. Combination
therapy with amikacin and
ceftolozane/tazobactam 29 and 89 the MIC at
an amikacin MIC of 8 mg/L resulted in a 2.2 and
4.6 log-kill, respectively, despite the isolate
being ceftolozane/tazobactam non-susceptible
(MIC 8 mg/L). Despite amikacin
non-susceptibility, synergistic activity was seen
with amikacin and ceftolozane/tazobactam
combination therapy at an amikacin
MIC[256 mg/L and ceftolozane/tazobactam
MIC of 2 mg/L (4.7 log-kill at 29 C/T MIC and
4.0 log-kill at 89 ceftolozane/tazobactam MIC).
DISCUSSION
To the best of our knowledge, this is the first
study to perform time-kill analyses of
ceftolozane/tazobactam alone and in
combination with other agents against P.
aeruginosa isolates from pediatric CF patients.
These data suggest that killing of P. aeruginosa
isolates appears to require concentrations of at
least 89 the ceftolozane/tazobactam MIC, with
the extent of ceftolozane/tazobactam activity
decreasing as MICs increase. Given the
multiples of ceftolozane/tazobactam MICs
tested, these data are likely in agreement with
Fig. 1 Mean bacterial densities of ﬁve P. aeruginosa
isolates over 24 h when exposed to multiple concentrations
of C/T alone and in combination with TOB and AMK.
a C/T MIC = 4 mg/L; TOB MIC [64 mg/L; AMK
MIC = 32 mg/L, b C/T MIC = 4 mg/L; TOB
MIC[64 mg/L; AMK = 16 mg/L; mucoid strain, c C/
T MIC = 0.5 mg/L; TOB MIC = 2 mg/L; AMK
MIC = 16 mg/L, d C/T MIC = 2 mg/L; TOB
MIC = 32 mg/L; AMK MIC[256 mg/L, e C/T
MIC = 8 mg/L; TOB MIC = 32 mg/L; AMK
MIC = 8 mg/L. MIC minimum inhibitory concentration;
for other abbreviatioms, see Table 1
c
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the concentration/MIC ratio of 6.6 suggested to
optimize the in vivo antibiotic effect of
ceftazidime against P. aeruginosa isolates from
CF patients [11]. Further, the retained activity of
ceftolozane/tazobactam against the tested
mucoid P. aeruginosa strain supports previously
published data, and suggests a potential role of
this antimicrobial against mucoid strains from
CF respiratory isolates [12]. The
pharmacokinetics of ceftolozane/tazobactam
in pediatric CF patients are yet to be
explained, but a phase-one, open-label study
evaluating the pharmacokinetics and safety of a
single IV dose of ceftolozane/tazobactam in
pediatric patients is currently enrolling
(NCT02266706) [13]. Yet, the preserved
ceftolozane/tazobactam MICs and
susceptibility of P. aeruginosa isolates from
pediatric CF patients reported here and in
other studies is promising when considering
the likelihood of attaining adequate
ceftolozane/tazobactam pharmacodynamic
targets [5].
The effect of tobramycin at concentrations
equal to the MIC appears greater in isolates with
a lower ceftolozane/tazobactam MIC. Overall, a
synergistic effect of ceftolozane/tazobactam and
tobramycin was evident among P. aeruginosa
isolates that were largely
ceftolozane/tazobactam and tobramycin
susceptible and among isolates with low-level
tobramycin resistance that remained
ceftolozane/tazobactam susceptible. While the
addition of tobramycin does not appear to
enhance ceftolozane/tazobactam activity in
isolates that are highly tobramycin resistant,
the addition of amikacin to
ceftolozane/tazobactam appears to provide
synergistic activity against highly-amikacin
resistant, ceftolozane/tazobactam-susceptible
strains. Additionally, synergistic activity of
amikacin and ceftolozane/tazobactam at 89
the MIC was seen when the isolate was
ceftolozane/tazobactam resistant but amikacin
susceptible.
The size of this study is a limitation, as only a
small number of isolates (n = 5) from a small
number of patients (n = 4) were evaluated.
CONCLUSION
Ceftolozane/tazobactam appears to be a
promising treatment option for treatment of
MDR P. aeruginosa in pediatric CF patients.
Interestingly, the benefit of
ceftolozane/tazobactam combination therapy
with amikacin may be more pronounced than
with the addition of tobramycin. Further
evaluation of such combination regimens is
warranted in pediatric CF patients, specifically
when a better understanding of
ceftolozane/tazobactam pharmacokinetics in
Fig. 1 continued
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this population has been elucidated and dosing
optimization strategies can be determined.
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